Serum soluble Talin-1 levels are elevated in patients with multiple sclerosis, reflecting its disease activity.

Previously, we identified anti-Talin-1 antibodies in the serum of MS. In this case, we measured the serum soluble Talin-1 (sTalin-1) levels by enzyme-linked immunosorbent assay. The serum sTalin-1 levels were significantly higher in 40 patients with MS than in 43 normal controls and in the acute phase of disease than in the remission phase. Interestingly, serum sTalin-1 levels were associated with a sustained increase in disability after MS attack but not with serum anti-Talin-1 antibody levels. sTalin-1 may be a biomarker for the acute phase of MS and may be used for the short-term prognosis of MS.

Talin 2 concentrations in cerebrospinal fluid in patients with epilepsy.

OBJECTIVES: Talin 2 plays an important role in cell adhesion and recycling of synaptic vesicles. To explore the possible role of talin 2 in epilepsy, we designed current study to quantitatively evaluate the changes in talin 2 levels in different epilepsy patients. DESIGN AND METHODS: We measured talin 2 levels in CSF and the serum of postencephalitic epilepsy (PEE) patients (subdivided into drug-refractory PEE-RPEE, and drug-effective PEE-EPEE groups) and acute encephalitis patients (subdivided into acute encephalitis with secondary seizures-AESS, and acute encephalitis without seizures-AE) by enzyme-linked immunosorbent assay. RESULTS: We found that, in RPEE patients, interictal CSF-talin 2 concentrations significantly increased, whereas serum-talin 2 significantly decreased when compared with the AE, AESS, and EPEE groups. CONCLUSIONS: This result suggested that the differential concentration of CSF and serum-talin 2 in the RPEE group is an intractability-related phenomenon that might be involved in the development of RPEE.

Proteomic analysis of cerebrospinal fluid from patients with idiopathic temporal lobe epilepsy.

Proteomic analysis of cerebrospinal fluid (CSF) from patients with temporal lobe epilepsy (TLE) and controls was carried out using two-dimensional gel electrophoresis followed by liquid chromatography electrospray ionization tandem mass spectrometry. Five protein spots showed significant differential expression (p<0.05): vitamin D-binding protein (DBP) was elevated in the CSF of TLE patients whereas cathepsin D, apolipoprotein J, Fam3c, and superoxide dismutase 1 (SOD1) were decreased in the CSF of TLE patients. Additional six protein spots presented only in the CSF of epilepsy patients were identified as tetranectin (TN), talin-2, apolipoprotein E, immunoglobulin lambda light chain (IGL@), immunoglobulin kappa variable light chain 1-5 (IGKV1-5), and procollagen C-endopeptidase enhancer 1 (PCOLCE). Expression of DBP, SOD1 and talin-2 was validated by western blot. Our results may provide better understanding of the pathophysiologic mechanisms underlying epileptogenesis and possible epilepsy biomarkers.